Gilead Releases Data From HIV Cure Research Program on Vesatolimod, GS-986
July 23 2019 - 5:25PM
Dow Jones News
By Stephen Nakrosis
Gilead Sciences, Inc. (GILD) on Tuesday released results from a
pair of studies conducted as part of its HIV cue research
program.
Gilead said 48 people living with HIV on antiretroviral therapy
took part in a double-blind, placebo-controlled Phase 1 clinical
study of vesatolimod, or GS-9620. Gilead said 36 of the
participants were given escalating doses of vesatolimod while the
others were given placebo. According to Gilead, "Vesatolimod at
higher doses stimulated a range of immune responses."
"This study demonstrates that vesatolimod can be administered to
people living with HIV at doses that may have immune effect and are
well-tolerated. The results support studies into the potential role
of vesatolimod as part of combination regimens aimed at achieving
ART-free control of HIV," said Sharon A. Riddler, Director of
Clinical Research in the Infectious Diseases Division, University
of Pittsburgh School of Medicine, and one of the study principal
investigators.
The second study saw two rhesus macaques receive oral doses of
the GS-986. The study indicated "GS-986 induced immune system
activation with observed increases in peripheral plasma
cytokines/chemokines and activation of immune cells," and was well
tolerated, Gilead said.
The data were presented at the International AIDS Society
Conference on HIV Science in Mexico City.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 23, 2019 17:10 ET (21:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024